INTRODUCTION
============

Gentle touch is sensed in the nematode *Caenorhabditis elegans* by six touch receptor neurons (TRNs; these cells are the 2 ALM, 2 PLM, 1 AVM, and 1 PVM neurons; [@B10]). Touch is transduced in the TRNs by the activation of a trimeric channel formed by two degenerin/epithelial sodium channel (DEG/ENaC) proteins, MEC-4 and MEC-10 ([@B47]; [@B2]; [@B14]). Previous work from our lab suggested that another protein, MEC-6, was also part of the mechanosensory channel complex in the TRNs, since it colocalized with MEC-4 in TRN neurites and coimmunoprecipitated with it in heterologous cells ([@B13]).

The sequence of MEC-6 and several other predicted *C. elegans* proteins ([@B13]) is similar to that of the three mammalian paraoxonases (PON1--PON3). Human PON1 and PON3 are serum proteins that contribute to high-density lipoprotein particles ([@B39]; [@B51]). In contrast, human PON2, which is ubiquitously expressed ([@B44]), localizes to the endoplasmic reticulum (ER; [@B32]; [@B53]). The exact function of these proteins is unclear, but they prevent lipid peroxidation ([@B3]; [@B55]; [@B46]; [@B51]; [@B6]; [@B19]; [@B35]), and PON1, but not PON2 or PON3, degrades the organophosphate paraoxon ([@B58]; [@B18]; [@B60]).

The localization and function of the mammalian paraoxonases suggest that MEC-6 may not be an integral component of the mechanosensory transduction complex but interacts with the channel-forming subunits elsewhere in the cell. Indeed, we recently found that MEC-6 does not colocalize with MEC-4 either on the plasma membrane of *Xenopus* oocytes or in TRN neurites ([@B14]). These results, when coupled to studies in *Drosophila melanogaster*, which has mechanosensory DEG/ENaC proteins ([@B38]; [@B71]; [@B26]; [@B28]; [@B40]) but no obvious MEC-6-like proteins ([@B31]), led us to reinvestigate the role of MEC-6 in *C. elegans* touch sensitivity.

Here we show that MEC-6 and a second paraoxonase-like protein that is expressed in the TRNs, [p]{.ul}ara[o]{.ul}xonase and [M]{.ul}EC-6-[l]{.ul}ike gene 1 (POML-1, previously named K11E4.3; [@B61]), primarily reside in the ER of the TRN cell body. Our results suggest that MEC-6 and POML-1 are important for MEC-4 production and localization.

RESULTS
=======

MEC-6 and POML-1 localize to the TRN endoplasmic reticulum
----------------------------------------------------------

The POML-1 sequence is 30% identical and 42% similar to that of MEC-6. Both MEC-6 ([@B13]) and POML-1 contain a transmembrane domain and a nematode-specific region of 15 amino acids in the N-terminus (Supplemental Figure S1A). In contrast to MEC-6, which is expressed in many cells ([@B13]), POML-1 was expressed in only a few neurons. In addition to the six TRNs ([@B61]), POML-1 was found in the IL1, AIM, ALN, and BDU neurons (Supplemental Figure S1B).

Rescuing and tagged translational fusions of MEC-6 and POML-1 are primarily expressed in the TRN cell body, with weak diffuse expression and puncta in the proximal TRN neurite (Supplemental Figure S1C; [@B14]). Using antibodies against tagged proteins, we usually saw POML-1 further along the TRN neurites (up to 100 μm of the ∼400-μm neurite) than MEC-6 (Supplemental Figure S1D). In the cell body, translational fusions for both proteins formed a perinuclear mesh-like structure that colocalized with markers for the ER (yellow fluorescent protein (YFP)::TRAM-1 and YFP::PISY-1, which label rough ER and general ER, respectively; [@B52]) and each other ([Figure 1, A--C](#F1){ref-type="fig"}), but not with a marker for the Golgi apparatus (AMAN-2::YFP; [Figure 1, D and E](#F1){ref-type="fig"}, and Supplemental Figure S1E). POML-1 partially overlapped with the Golgi marker in 3 of 10 cells (Supplemental Figure S1E).

![TRN expression of MEC-6 and POML-1. Confocal sections of TRN cell bodies of (A) MEC-6::TagRFP and the ER marker YFP::TRAM-1, (B) POML-1::TagRFP and the ER marker YFP::PISY-1, (C) MEC-6::TagRFP and POML-1::YFP, and (D) MEC-6::TagRFP and the Golgi marker AMAN-2::YFP and their correlation coefficient (E). Scale bars, 5 μm (A--D, F--H, J--L). The number of examined TRNs is given in parentheses (E, I). Symbols for significance here and in all subsequent figures are described in *Materials and Methods*. Neurite expression of (F) POML-1::YFP and MEC-6::TagRFP, (G) POML-1::YFP and MEC-4::TagRFP, and (H) POML-1::YFP and MEC-2 and their correlation coefficient (I). Anti-GFP and anti-MEC-2 antibodies (Ab) were used to label the proteins in (H). (J) MEC-6::3XFLAG expression as detected by an anti-FLAG antibody in intact (top) and permeabilized (bottom) cultured TRNs. (K) POML-1::YFP expression as detected by an anti-GFP antibody in intact (top) and permeabilized (bottom) TRNs in culture. The faint immunofluorescence in intact cells (J, K) was not specific because it was often observed in cells that did not express MEC-6::3XFLAG or POML-1::YFP. Images in J and K are representative of 40 cells examined in two independent experiments. (L) MEC-4 expression detected with an anti-MEC-4 antibody that recognizes the extracellular domain in intact (top) and permeabilized (bottom) cultured TRNs. Images are representative of 20 cells examined in two independent experiments.](1272fig1){#F1}

When seen, MEC-6 and POML-1 puncta colocalized in the proximal TRN neurite ([Figure 1F](#F1){ref-type="fig"}). As with MEC-6 ([@B14]), POML-1 puncta differed from and did not colocalize with MEC-4::TagRFP or MEC-2 puncta in TRN neurites ([Figure 1, G--I](#F1){ref-type="fig"}), although some overlap was observed. General ER but not rough ER is also present in TRN neurites (Supplemental Figure S1F; [@B52]). In general, POML-1 puncta (of the cells represented in [Figure 1, F and G](#F1){ref-type="fig"}) were smaller and closer together than the MEC-4 and MEC-2 puncta: POML-1 puncta were 0.90 ± 0.02 μm wide and separated by 1.17 ± 0.08 μm (25 PLM neurites), and MEC-2 puncta were 1.95 ± 0.05 μm wide and separated by 3.86 ± 0.13 μm (30 PLM neurites; *p* \< 0.0001 for both puncta width and the distance between puncta for POML-1::YFP and MEC-2).

Consistent with the ER localization of MEC-6 and POML-1, we found that both proteins were absent from the TRN surface. Previous work suggested that MEC-6 was a membrane protein that extended its C-terminus extracellularly ([@B13]). Specifically, LacZ fused to the C-terminus of MEC-6 produced no β-galactosidase activity unless a synthetic transmembrane domain was inserted between MEC-6 and LacZ (LacZ produces β-galactosidase activity only intracellularly). We found that POML-1 acted similarly (Supplemental Figure S1G). This result suggests that the C-termini of MEC-6 and POML-1 are not located in the cytoplasm but are either outside the cell or in the lumen of an internal organelle. MEC-6 was glycosylated when expressed in CHO cells, and C-terminally hemagglutinin (HA)-tagged MEC-6 was detected by surface immunostaining against HA tags in CHO cells ([@B13]). However, in cultured TRNs from wild-type embryos (using antibodies directed against C-terminal tags of MEC-6 and POML-1), we were able to detect the proteins only when the cells were permeabilized, indicating the absence of both MEC-6 and POML-1 expression on the cell surface ([Figure 1, J and K](#F1){ref-type="fig"}; 40 cells for each). On the contrary, an antibody recognizing the extracellular region of MEC-4 detected clear expression of MEC-4 on the cell surface in intact cells ([Figure 1L](#F1){ref-type="fig"}; 20 cells). Because MEC-6 and POML-1 could be expressed, albeit weakly, on the surface of *Xenopus* oocytes (Supplemental Figure S1H; [@B14]) and CHO cells in previous experiments ([@B13]), either control over the subcellular localization is tighter in the TRNs or a small, undetected amount of MEC-6 and POML-1 goes to the TRN surface. Most of MEC-6 and POML-1, however, was detected in the TRN ER.

The foregoing fusion constructs, including *poml-1::yfp*, *poml-1::tagrfp*, *mec-4::tagrfp*, *mec-6::3Xflag*, and *mec-6::tagrfp*, produced functional products, since they could rescue *poml-1*, *mec-4*, and *mec-6* null mutations (Supplemental Figure S1I; [@B14]).

POML-1 affects the function of MEC-4
------------------------------------

The failure of POML-1 to colocalize with MEC-4 suggests that POML-1 may not function directly in transduction. To study the role of *poml-1* gene, we first generated *poml-1* null alleles. Using Mos1-mediated gene deletion ([@B22]; [@B23]), we obtained two null mutations, *u881* and *u882*, which lacked the entire *poml-1* coding sequence. We obtained four additional mutations using ethyl methanesulfonate mutagenesis: three splicing junction mutations (*u851*, *u852*, and *u853*) and one missense mutation (*u854*; Supplemental Figures S1A and S2A). Two *poml-1* alleles (*ok2266* and *tm4234*; Supplemental Figures S1A and S2A) with the gene partially deleted were previously known. For many of the experiments, we used the *ok2266* allele, which acted as a null, since it produced the same phenotype as *poml-1(u881;* see later discussion).

None of the eight mutations produced touch insensitivity or any other obvious phenotype. The mutations, however, did render animals containing sensitizing mutations touch insensitive ([Figure 2A](#F2){ref-type="fig"} and Supplemental Figure S2B). These sensitizing mutations were temperature-sensitive alleles of *mec-4* and *mec-6* ([@B27]), two hypomorphic alleles of *mec-6* (*u511*(G235E) and *u518*(G213E); [@B24]), and null alleles of *crt-1*, which encodes the ER chaperone calreticulin ([@B49]; [@B66]). Except for the *crt-1* mutations, which lower MEC-4 protein level and cause slight touch defects ([@B66]), none of the sensitizing mutations produced touch insensitivity on their own. All of the mutations produced severe touch insensitivity in *poml-1* null mutants. These synthetic phenotypes suggest a role for *poml-1* in TRN touch sensitivity. The loss of MEC-6, POML-1, or CRT-1 did not affect the general physiology of the TRNs, since light activation of TRN-expressed channelrhodopsin-2 ([@B45]) produced the same response in *crt-1*, *mec-6; poml-1*, and *crt-1; poml-1* mutants as in wild type (Supplemental Figure S2C).

![POML-1 is required for touch sensitivity and *mec-4(d)--*induced TRN degeneration. (A) *poml-1(u882)* reduced the touch response to 10 touches in sensitized backgrounds (30 animals were examined in three independent experiments). (B) *poml-1* and *mec-6* mutations suppress *mec-4*(*d*) degenerations. *n*, number of animals examined. TRNs labeled with GFP in L4 and young adult animals were scored as having survived. *uIs83* is an integrated array that overexpresses *mec-4*(*d*). The rescue experiments used three to five stable lines.](1272fig2){#F2}

Other evidence for a role of POML-1 in MEC-4 function comes from the suppression by *poml-1* mutations of the TRN degeneration caused by the hyperactive channel encoded by the *mec-4(d)* gain-of-function mutation *e1611* ([@B20]; [@B8]). *mec-6* mutations, but not those of other touch sensitivity genes, suppressed these deaths ([@B11]; [@B34]). In contrast to their weak effects on touch sensitivity, seven of the eight *poml-1* alleles (all but the missense mutation *u854*) strongly suppressed *mec-4(d)* neuronal degeneration to different extents ([Figure 2B](#F2){ref-type="fig"}) and did so on their own. The suppressed animals were all touch insensitive, suggesting that either insufficient MEC-4(d) is available for touch sensitivity or the mutant channels cannot transduce touch.

Overexpressing *poml-1(+)* rescued the *poml-1* phenotype in *poml-1 mec-4*(*d*) animals (resulting in TRN degeneration) but not the *mec-6* phenotype in *mec-6 mec-4*(*d*) animals ([Figure 2B](#F2){ref-type="fig"}). Similarly, overexpressing *mec-6(+)* caused almost all of the TRNs to die in *mec-6 mec-4*(*d*) animals but only 35% of the TRNs in *poml-1 mec-4*(*d*) animals ([Figure 2B](#F2){ref-type="fig"}). These results suggest that *mec-6* and *poml-1* have activities that cannot be replaced by the other gene.

Overexpressing *mec-4(d)* by the multiple-copy insertion *uIs83* partially caused degeneration in *poml-1* animals but not in animals with the *mec-6(u450)* mutation ([Figure 2B](#F2){ref-type="fig"}), which deletes most of the *mec-6* coding sequence and is considered to be a null allele ([@B13]). Unlike *mec-6* mutations ([@B11]; [@B57]), *poml-1* mutations did not suppress other DEG/ENaC gain-of-function mutations, including *deg-1* (Supplemental Figure S2D) and *unc-8* (20 of 20 animals were still Unc), even though POML-1 and DEG-1 are both expressed in IL1 neurons.

POML-1 modulates MEC-4(d) channel activity in *Xenopus* oocytes
---------------------------------------------------------------

As with MEC-6 ([@B13]), POML-1 increased the activity of the MEC-4(d) channel in *Xenopus* oocytes ([Figure 3A](#F3){ref-type="fig"} and Supplemental Figure S3A). POML-1 increased the amiloride-sensitive Na^+^ current by threefold, a smaller effect than the 10-fold increase produced by MEC-6. In addition, N-terminally enhanced green fluorescent protein (EGFP)--tagged POML-1 and N-terminally Myc-tagged MEC-4(d) immunoprecipitated each other in oocytes ([Figure 3B](#F3){ref-type="fig"}). Moreover, POML-1 also immunoprecipitated C-terminally HA-tagged MEC-6 ([Figure 3B](#F3){ref-type="fig"}), which is consistent with their colocalization in the ER and suggests that they physically interact. Like MEC-6, POML-1 worked synergistically with MEC-2, but not with MEC-6, to increase channel activity ∼40-fold ([Figure 3A](#F3){ref-type="fig"}). MEC-2, a stomatin-like protein that binds cholesterol, increases MEC-4 channel activity both in vivo and in vitro, perhaps through modulating the lipid environment surrounding the channel ([@B25]; [@B47]; [@B33]). At higher concentrations, POML-1 on its own, like MEC-6 ([@B13]), produced an amiloride-resistant current in oocytes (Supplemental Figure S3, B and C).

![The effect of POML-1 on MEC-4(d) channel activity and their physical interaction in *Xenopus* oocytes. (A) Effect of POML-1 (white bars) on the MEC-4(d) amiloride-sensitive current at −85 mV in oocytes. The number of oocytes tested is given in parentheses. The oocytes were from at least two frogs. (B) Immunoprecipitation (IP) of POML-1 with MEC-4(d) and MEC-6 expressed in oocytes. IB, immunoblot probe. Images are representative of two or three independent experiments. Molecular weights (kilodaltons) of the protein markers are indicated on the right. EGFP::POML-1 is functional, since its coexpression with MEC-4(d) generated amiloride-sensitive currents (EGFP::POML-1 and Myc::MEC-4(d), *I*~amil~ = −1.4 ± 0.3 μA, *n* = 5) that were similar to those of coexpressing untagged POML-1 and MEC-4(d) (*I*~amil~ = −1.6 ± 0.6 μA, *n* = 5) 6 d after cRNA injection. The negative control (--) is EGFP with the same tag.](1272fig3){#F3}

POML-1 and MEC-6 affect the amount and distribution of MEC-4
------------------------------------------------------------

Because POML-1 and MEC-6 affected MEC-4 channel function in vivo and channel activity in oocytes ([Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}), we next tested their effect on the production and distribution of MEC-4. We examined wild-type MEC-4 expression in cultured TRN cells with anti-MEC-4 antibodies. Both total expression (detected in permeable cells) and surface expression (detected in intact cells) of MEC-4 were substantially reduced by *mec-6* and *poml-1* mutations. MEC-4 surface expression was barely detected in cells with a *mec-6* null mutation and was reduced by 50% in cells with a *poml-1* null mutation ([Figure 4, A and B](#F4){ref-type="fig"}). MEC-4 partially colocalized with ER and endosome markers in wild-type TRN cell bodies but not with Golgi markers ([Figure 4C](#F4){ref-type="fig"}). Less MEC-4 protein appeared in the TRN cell bodies in *mec-6* and *poml-1* mutants, but the localization of MEC-4 vis-à-vis the ER, endosome, and Golgi markers did not dramatically change ([Figure 4, C and D](#F4){ref-type="fig"}).

![MEC-4 expression in cultured TRNs with *mec-6(u450)* or *poml-1(ok2266)* mutation. Images (A) and quantification (B) of MEC-4 expression as detected by an anti--MEC-4 antibody in intact (left) and permeabilized (right) TRNs in culture. MEC-4 immunofluorescence intensity was normalized to that of wild-type (WT) TRNs. Scale bars, 5 μm (A, C). Because most cell bodies leaked after immunostaining for intact cells (as evident by the staining for MEC-18, a cytoplasmic protein), immunofluorescence was only measured for MEC-4 surface expression in intact neurites (which did not show MEC-18 staining; *Materials and Methods*). Statistical significance is indicated for comparison with the WT cells by one-way ANOVA with Tukey post hoc (B, D). The number of cell bodies tested from two or three experiments is given in parentheses (B, D). The subcellular localization of MEC-4 and markers for the ER, endosome, and Golgi (C) in cultured TRNs and their correlation coefficient (D).](1272fig4){#F4}

We also examined MEC-4 expression in vivo using a fluorescent protein tag and an anti--MEC-4 antibody. Tagged MEC-4, which produced very strong fluorescence, appeared as large spots in the TRN cell body and smaller puncta in the neurite ([Figure 5A](#F5){ref-type="fig"}; in some cases, the spots were less prominent in the cell body, and a meshwork was seen). Such MEC-4 aggregates were also detected by the anti-MEC-4 antibody in cell bodies, although this fluorescence was much less bright (under these conditions, the diffuse expression was more obvious). In the cell body, MEC-4::TagRFP spots partially colocalized with POML-1 ([Figure 5B](#F5){ref-type="fig"}) and the ER (YFP::TRAM-1), but some were always adjacent to the Golgi (AMAN-2::YFP; 20 TRNs) and the ER exit site (SEC-23::GFP; 10 TRNs; Supplemental Figure S4A). Thus MEC-4 may reside, at least for some time, in ER--Golgi intermediate compartment ([@B1]) or *trans*-Golgi network ([@B63]).

![Effect of *mec-6*, *poml-1*, and *crt-1* mutations on MEC-4 and MEC-2 expression in the TRNs. Unless noted, the following mutations were used: *crt-1(ok948)*, *mec-4(u253)*, *mec-5(u444)*, *mec-6(u450)*, *uba-1(it129)*, and *poml-1(ok2266)*. (A) MEC-4::TagRFP expression. Left, merged images of expression at 10 focal planes; right, images of the single plane showing the best-focused image of the same cell body. Scale bar, 5 μm (A--C). (B) Confocal images of MEC-4::TagRFP and POML-1::YFP in the TRN cell body of WT animals (top) and *mec-6(u450)* mutants (bottom). Their correlation coefficient is 0.2 ± 0.04 and 0.7 ± 0.04 in WT and *mec-6* mutants (10 TRNs), respectively. (C) MEC-2 expression in the TRN neurite. Representative of 20--30 TRNs examined in two experiments. (D) MEC-4::TagRFP fluorescence intensity (normalized to WT) in PLM cell bodies of L4 larvae and young adults of controls and *mec-6(u450)*, *poml-1*, and *crt-1* without (black) or with (white) a *uba-1* mutation. For each pair of white and black bars, the effect of the *uba-1* mutation was significant at *p* \< 0.001, except for WT, for which it was at *p* \< 0.01. The comparison to the control within each group (with or without *uba-1*) was significant at *p* \< 0.001 by two-way ANOVA with Bonferroni posttest. The number of examined PLM cells collected from three independent experiments is given in parentheses (D, E). (E) Fluorescence intensity of MEC-4::TagRFP (normalized to WT control) in PLM cell bodies of WT and mutants either untreated (black) or treated (white) with 50 μM bortezomib for 8 h. Statistical comparisons are as in D, with the exception that the difference between treated and untreated WT animals was not significant.](1272fig5){#F5}

Consistent with the results seen in cultured TRNs, *mec-6* and *poml-1* mutations reduced MEC-4 protein levels in vivo as seen with fusion proteins ([Figure 5A](#F5){ref-type="fig"}) and an anti-MEC-4 antibody (Supplemental Figure S4B). As in cultured TRNs ([Figure 4, A--B](#F4){ref-type="fig"}), the reduction was stronger with *mec-6* in vivo (Supplemental Figure S4, B and C) and thus correlates with the stronger phenotype of *mec-6* with regard to touch sensitivity and *mec-4(d)* degeneration. Proteins were found mainly in the perinuclear mesh-like structure in the TRN cell body, indicating the ER, and puncta were not seen in the neurites. Indeed, in the TRN cell body with *mec-6* mutations, MEC-4 fusion proteins colocalized with POML-1 in the ER ([Figure 5B](#F5){ref-type="fig"}). In addition, the half-maximal pressure (*P*~1//2~) for the mechanoreceptor current (MRC) differed slightly between *poml-1* and wild-type TRNs (*poml-1 P*~1/2~ = 7.7 ± 0.8 nN/μm^2^ vs. wild-type *P*~1/2~ = 4.5 ± 0.7 nN/μm^2^, mean ± SD; Supplemental Figure S4D), but *poml-1* mutations did not affect MRC peak amplitude or kinetics (Supplemental Figure S4E). The effects of *mec-6* and *poml-1* mutations on MEC-4 appeared to be specific because they did not affect the expression of each other (Supplemental Figure S5A) or of MEC-18 (Supplemental Figure S4B).

The effect of *mec-6* and *poml-1* mutations was similar to that of a *crt-1* null mutation, which also reduced the amount of MEC-4 and its appearance as puncta in TRN cell bodies and neurites ([Figure 5A](#F5){ref-type="fig"}). We found that MEC-6, POML-1, and CRT-1 affected the expression and distribution of MEC-4 protein rather than the amount of *mec-4* mRNA as detected by single-molecule fluorescence in situ hybridization (the *crt-1* mutation slightly increased the number of *mec-4* mRNA molecules in TRN; Supplemental Figure S5B).

The effects of *mec-6* and *poml-1* mutations on MEC-4 protein levels and distribution suggest that MEC-6 and POML-1 act early in MEC-4 production and/or transport. Consistent with this hypothesis, mutations that presumably affect touch sensitivity after MEC-4 is made (e.g., null mutation of *mec-5*, a gene encoding an extracellular matrix collagen needed for touch sensitivity; [@B21]) disrupted the neurite localization of MEC-4 without affecting the level of MEC-4 protein (normalized intensity of MEC-4::TagRFP in the cell body: wild-type 1 ± 0.06 vs. *mec-5(u444)* 0.92 ± 0.05; 29 PLM cells; not significant by the Student's *t* test) or its distribution in the cell body ([Figure 5A](#F5){ref-type="fig"}).

Because the production of MEC-2 puncta requires MEC-4 ([@B21]; [@B69]), we also tested the role of POML-1 on MEC-2 distribution using an anti--MEC-2 antibody in *poml-1* mutants, the two *mec-6* hypomorphic mutants *u511*(G235E) and *u518*(G213E), *crt-1* mutants, and *mec-6 (u511); poml-1, mec-6 (u518); poml-1* and *crt-1; poml-1* double mutants. No single mutation caused obvious defects in MEC-2 puncta. In contrast, the double mutants, as in the null mutants of *mec-4* and *mec-6*, had disrupted MEC-2 puncta ([Figure 5C](#F5){ref-type="fig"}), a result that is consistent with the need for the double mutations to cause touch insensitivity.

MEC-6 and POML-1 likely act as chaperones
-----------------------------------------

The similarity of the phenotypes of *crt-1*, *mec-6*, and *poml-1* mutants, the expression of all three proteins primarily in the ER, and the additivity of their phenotypes with regard to touch sensitivity suggest that MEC-6 and POML-1, like CRT-1, may, at least in part, act as chaperones. If these proteins facilitate the folding/assembly of MEC-4 in the ER, the reduction in MEC-4 protein in these mutants could be a consequence of increased protein degradation. Indeed, the loss of CRT-1, MEC-6, or POML-1 caused an increase in MEC-4 degradation. Mutation of the ubiquitin-activating (E1) enzyme gene *uba-1* ([@B36]) or treatment of animals with the proteasome inhibitor bortezomib increased MEC-4 levels twofold to threefold in *mec-6*, *poml-1*, and *crt-1* mutants ([Figure 5, D and E](#F5){ref-type="fig"}). *uba-1* mutation, but not bortezomib, affected the removal of wild-type MEC-4 from the cell surface ([@B17]). The effects of bortezomib on MEC-4 levels in the *mec-6*, *poml-1*, and *crt-1* mutants thus reveal a different process, perhaps a consequence of the accumulation of misfolded protein.

This increase, however, did not restore MEC-4 levels to those seen in wild type, in part, perhaps, because less MEC-4 protein was produced in *mec-6*, *poml-1*, and *crt-1* mutants even when the degradation pathway was blocked or the *uba-1* mutation and bortezomib treatment only partially suppressed the degradation pathway. Although these treatments increased the amount of MEC-4, they did not change its distribution. MEC-4 was still largely restricted to the same mesh-like structure at perinuclear sites in the cell body seen in the mutants without the *uba-1* mutation or bortezomib treatment ([Figure 5A](#F5){ref-type="fig"} and Supplemental Figure S5C). Moreover, the MEC-4 puncta were not restored in TRN neurites (Supplemental Figure S5C). In addition, because *uba-1* mutation did not restore touch sensitivity to *mec-6* null mutants or *crt-1; poml-1* double mutants (Supplemental Figure S5D) and resulted in only a modest increase (16% in ALM for *uba-1*) of touch cell deaths in *poml-1 mec-4(d)* animals but not in *mec-6; mec-4*(*d*) animals (Supplemental Figure S5E), the increased MEC-4 does not function, perhaps because it is misfolded or not properly localized.

Because overexpression of the ER transport protein SEC-24 rescued the trafficking defects caused by the loss of a putative ER chaperone/cargo receptor but not the folding defects in yeast ([@B48]), we tested whether overexpression of *C. elegans sec-24* genes (*sec-24.1* and *sec-24.2*) in the TRNs could similarly suppress the effects of *crt-1*, *mec-6*, and *poml-1* mutations (CRT-1 is also required for the degeneration caused by hyperactive MEC-4(d) channels; [@B66]). The effects were partial: ∼50% of the TRNs died in *poml-1 mec-4(d)* animals and 30% in *crt-1; mec-4(d)* animals, but no TRNs died in *mec-6; mec-4(d)* animals overexpressing the *sec-24* genes ([Figure 6A](#F6){ref-type="fig"}). We also noticed that overexpression of *sec-24(+)* caused morphological defects: wavy neurites, extra neurites, and misplaced cell bodies; these defects were rarely seen in animals that did not overexpress *sec-24(+)* (Supplemental Figure S5F). In addition, the overexpression of the *C. elegans sec-24* genes with mutated potential cargo-binding sites (corresponding to yeast SEC-24 R230A, R235A, L616W; [@B42]) reduced but did not eliminate the effect; 20% of the TRNs died in *poml-1 mec-4*(*d*) animals ([Figure 6A](#F6){ref-type="fig"}). Although overexpressing SEC-24 in *poml-1* mutants doubled the amount of MEC-4::TagRFP in proximal TRN neurites but not in the cell bodies ([Figure 6B](#F6){ref-type="fig"}), it did not restore touch sensitivity to *mec-6(u511); poml-1* animals (0.21 ± 0.09 response to 10 touches; 20 animals).

![MEC-6, POML-1, and CRT-1 may function as chaperones. The mutations *mec-6(u450)*, *poml-1(ok2266)*, and *crt-1(ok948)* were used. (A) The effect of *sec-24.1* and *sec-24.2* overexpression, *uEx*\[*sec-24(+)*\], on the suppression of *mec-4*(*d*) deaths by *poml-1*, *crt-1*, and *mec-6* mutations. In some strains, the cargo-binding sites of *sec-24.1* and *sec-24.2* were mutated (*sec-24(m)*). *n*, number of animals examined. The results with *uEx\[sec-24(+)\] and uEx\[sec-24(m)\]* were collected from two to five stable lines. (B) Effect of overexpressing *sec-24(+)* on MEC-4::TagRFP fluorescence intensity in the PLM cell bodies and proximal neurites of L4 larvae and young adults with the *poml-1* mutation. Data for *uEx\[sec-24(+)\]* were collected from two stable lines. The number of PLM cells examined is given in parentheses. Fluorescence intensity was normalized to that of PLM in *poml-1* mutants (control). Scale bar, 5 μm. (C) Schematic of CFP::MEC-4::YFP protein (left) and images of CFP::MEC-4::YFP in the TRN cell body taken with the CFP (blue), FRET (red), and YFP (yellow) channels, respectively (right). The Net FRET signal is given by a pseudocolored image to show the relative intensity. (D) The normalized FRET signal (see *Materials and Methods*) of CFP::MEC-4::YFP either in the TRN cell bodies (white bars) of WT animals and mutants or in the puncta of WT animals (black bar). The number of cell bodies or strongly fluorescent puncta tested (from two or three stable lines with extrachromosomal arrays collected from three of four experiments) is given in parentheses. Statistical significance is indicated for comparison with the FRET signal in the WT cell body. (E) CFP::MEC-4::YFP intensity (measured in the YFP channel and normalized to that WT controls) and FRET signals in the TRN cell body of WT, *mec-6*, *poml-1*, and *crt-1* animals treated with bortezomib. The number of examined cells bodies here and in F is indicated in parentheses. These experiments used cells from an integrated line, which produced similar FRET signals to the stable lines with extrachromosomal arrays used in D. Bortezomib treatment had a significant effect on CFP::MEC-4::YFP intensity (left, *F*(1, 58) = 33.56, *p* \< 0.0001) but no effect on the FRET signal (right, *F*(1, 58) = 0.01, *p* = 0.9162, by two-way ANOVA with Bonferroni posttests). The value above the bracket is that of the pairwise comparison. The values below the bracket are for the comparison to the WT of each untreated (black bars) or treated group (white bars) by two-way ANOVA with Bonferroni posttests. The difference in CFP::MEC-4::YFP fluorescence intensity (left) between control WT and bortezomib-treated *mec-6*, *poml-1*, and *crt-1* mutants was not significant. (F) FRET signals in *mec-6* and *poml-1* animals overexpressing *sec-24(+)* in TRNs.](1272fig6){#F6}

These results can be explained if little, if any, MEC-4 folds in *mec-6* mutants, but some MEC-4 folds but is not transported to the surface in *poml-1* and *crt-1* mutants. Thus, by increasing transport to the surface, SEC-24 could cause more *mec-4(d)*-induced deaths in the *poml-1* and *crt-1* mutants but not in the *mec-6* mutants because they contain no functioning protein. These results suggest an absolute need for MEC-6 in MEC-4 expression and distribution and are consistent with the need for MEC-6 ([@B10]), but not of POML-1 and CRT-1, in touch sensitivity in wild-type animals ([Figure 2A](#F2){ref-type="fig"}).

CRT-1 can bind Ca^2+^ and regulate Ca^2+^ homeostasis in the ER ([@B41]). [@B66] suggested that *crt-1* suppression of MEC-4(d)--induced cell death can be attributed to the Ca^2+^-binding capacity of CRT-1 in the ER and partially reversed by the release of ER Ca^2+^ induced by thapsigargin. We tested whether *poml-1* and *mec-6* suppress MEC-4(d) through a similar mechanism and found that, in contrast to *crt-1*, the effect of *poml-1* and *mec-6* on cell death was not affected by thapsigargin treatment (Supplemental Figure S5G). Thus *poml-1* and *mec-6* mutations are less likely to suppress MEC-4(d)--induced cell death by affecting the subcellular Ca^2+^ level. Moreover, manipulating the subcellular Ca^2+^ level has no effect on MEC-4 expression ([@B66]). Therefore *mec-6* and *poml-1* suppression of MEC-4(d) is primarily due to their effect on MEC-4 expression and distribution.

Because Förster resonance energy transfer (FRET) can be used to monitor protein folding ([@B50]), we used a cyan fluorescent protein (CFP)::MEC-4::YFP fusion to examine whether MEC-6, POML-1, and CRT-1 affect the MEC-4 protein folding. This fusion was expressed in the TRNs: as with MEC-4::GFP and MEC-4::TagRFP, the protein formed regular puncta in the neurite (Supplemental Figure S5H) and a mesh-like structure and spots in the cell body, although the spots in the cell body were smaller and dimmer than with MEC-4::TagRFP ([Figure 6C](#F6){ref-type="fig"}). In *mec-6, poml-1*, or *crt-1* mutants, CFP::MEC-4::YFP was restricted to the cell body, where the fluorescence intensity was reduced by nearly 50% ([Figure 6C](#F6){ref-type="fig"}). CFP::MEC-4::YFP produced an efficient FRET signal in wild-type animals ([Figure 6, C and D](#F6){ref-type="fig"}), suggesting that CFP and YFP were close to each other.

In contrast to the FRET signal in wild type, FRET from CFP::MEC-4::YFP was reduced by 70--80% in *mec-6, poml-1*, or *crt-1* mutants ([Figure 6, C and D](#F6){ref-type="fig"}). The reduction of FRET in these mutants was not due to reduced CFP::MEC-4::YFP expression, because the FRET signal was normalized to the CFP and YFP intensities (see *Materials and Methods*), and wild-type animals expressing similar level of CFP::MEC-4::YFP to these mutants (from *uIs190(mec-4p::cfp::mec-4::yfp)/+* animals) produced robust FRET signals (normalized FRET: 0.24 ± 0.06, *n* = 5). Moreover, bortezomib treatment increased CFP::MEC-4::YFP expression in *mec-6, poml-1*, and *crt-1* mutants to a level similar to that in wild-type untreated animals but had no effect on the FRET signal ([Figure 6E](#F6){ref-type="fig"}). These data suggest that the folding and/or assembly of MEC-4 is compromised in these mutants. Overexpression of SEC-24 also failed to increase the FRET signals in *mec-6* and *poml-1* mutants ([Figure 6F](#F6){ref-type="fig"}), a result that is consistent with the role for SEC-24 in protein transport but not in protein folding.

Given the localization of MEC-6 and POML-1 in the ER and their potential effects on folding, we wondered whether *mec-6* or *poml-1* mutations induced a general ER stress response. These mutations, however, did not significantly change the expression of *xbp-1b::gfp* (Supplemental Figure S5I), which produces a GFP translation product only in response to ER stress ([@B56]). Wild-type and the mutant strains showed a similar ER stress response when proteasomes were inhibited by bortezomib (Supplemental Figure S5I).

MEC-6 accelerates the surface expression of MEC-4 in *Xenopus* oocytes
----------------------------------------------------------------------

Consistent with its role as a chaperone, we found that MEC-6 greatly increased the amount of surface expression of MEC-4 in *Xenopus* oocytes, using total internal reflection fluorescence (TIRF) microscopy and biotinylation ([Figure 7, A--D](#F7){ref-type="fig"}) 2 d after complementary RNA (cRNA) injection. In contrast, MEC-2 and POML-1 did not increase the surface expression of MEC-4 ([Figure 7, A--D](#F7){ref-type="fig"}). Although TIRF microscopy cannot be used to determine the position of the protein on the plasma membrane, the biotinylation experiments suggest that MEC-6 affects MEC-4 surface expression. These results support the hypothesis that MEC-6 assists the maturation of MEC-4 channels and/or its transport to the plasma membrane.

![Effect of MEC-6 and POML-1 on MEC-4 surface expression in *Xenopus* oocytes. (A) Images and (B) quantification of MEC-4::EGFP fluorescent spots on the oocyte surface visualized by TIRF imaging (19--29 patches from 14--16 cells from two different batches) 2 d after cRNA injection. Values are compared with the expression of MEC-4::EGFP alone using the Mann--Whitney test. The field dimensions are 13 μm × 13 μm. (C) Western blot of Myc::MEC-4(d) on the surface of oocytes as detected by biotinylation (top) and the expression of Myc::MEC-4(d) in total lysate of oocytes (middle) at 2 d after cRNA injection. β-Actin detected in total lysate was used as an input control (bottom). Molecular weights (kilodaltons) of the protein markers are indicated on the right. (D) Quantification of changes in surface Myc::MEC-4(d) detected by biotinylation at 2 d after cRNA injection (the number of independent experiments is given in parentheses). All data are normalized and compared with Myc::MEC-4(d) expression alone by the one-sample *t* test. MEC-6, MEC-2, and POML-1 did not affect Myc::MEC-4(d) levels in total lysates at 2 d after injection (MEC-6, 1.0 ± 0.1; MEC-2, 1.0 ± 0.1; POML-1, 0.9 ± 0.1; four or five independent experiments, normalized and compared with the expression of Myc::MEC-4(d) alone; not significant by one-sample *t* test). The normalized amount of total Myc::MEC-4(d) differed by no more than 25% in any of the experiments. (E) The amiloride-sensitive MEC-4(d) current at −85 mV (12--18 oocytes \[2 d after cRNA injection\] or 6--12 oocytes \[other times\] of three batches) on its own and in the presence of MEC-2, MEC-6, and POML-1 at various times after cRNA injection. *p* \< 0.001 for *I*~amil~ at −85 mV between oocytes 2 d after injected with MEC-4(d) and MEC-6 vs. MEC-4(d) alone, MEC-4(d) and MEC-2, or MEC-4(d) and POML-1; no statistically significance was found between oocytes 2 d after injection with MEC-4(d) alone vs. MEC-4(d) and MEC-2, or MEC-4(d) and POML-1. *p* \< 0.001 for *I*~amil~ at −85 mV between oocytes 1 d after injected with MEC-4(d) and MEC-6 vs. MEC-4(d) alone; *p* \< 0.01 between MEC-4(d) and MEC-6 vs. MEC-4(d) and MEC-2, or MEC-4(d) and POML-1. One-way ANOVA with Tukey post hoc.](1272fig7){#F7}

The effect of MEC-6 on MEC-4(d) surface expression in oocytes was not seen 5 d after injection by biotinylation (Supplemental Figure S6A), which is consistent with previous experiments ([@B13]; [@B9]). Presumably, the maximum steady-state amount of MEC-4 is found on the surface with or without MEC-6 by 5 d. The lack of an effect in those previous experiments is due, at least in part, to the longer period of expression and presumably to the accumulation of more inactive MEC-4 in the absence of MEC-6.

We also tested whether the early, MEC-6-induced change in membrane-associated MEC-4 affected the MEC-4(d) current in oocytes. Indeed, MEC-6, but not MEC-2 or POML-1, increased the MEC-4(d) current \>30-fold to nearly 50% of the maximum current 2 d after injection ([Figure 7E](#F7){ref-type="fig"}; the fold difference is greater here than before \[ [Figure 3A](#F3){ref-type="fig"}\] because these oocytes had been injected with the lesser amount of *mec-4* cRNA, so the MEC-4(d) current was lower). The early effect of MEC-6 compared with POML-1 and MEC-2 on MEC-4(d) activity 2 d after injection was due to different amounts of surface MEC-4(d) rather than of total MEC-4(d) ([Figure 7, C and D](#F7){ref-type="fig"}). Differences in the timing of MEC-6, MEC-2, and POML-1 expression were unlikely to cause these differences in the MEC-4(d) current. MEC-6, MEC-2, and POML-1 were all expressed well 2 d after injection, and all had higher expression level 5 d after injection (Supplemental Figure S6, B--D). In addition, although injecting oocytes with greater amounts of *mec-2* and *poml-1* cRNA increased the levels of total MEC-2 and POML-1 at 2 d after injection to the levels normally seen at 5 d after injection (Supplemental Figure S6, C and D), MEC-4(d) currents 2 d after injection were not increased (Supplemental Figure S6, E and F).

In addition to MEC-6 increasing MEC-4 membrane expression, it also increased, albeit weakly, the membrane expression of MEC-2 in oocytes (Supplemental Figure S6, G and H). In contrast, although coexpression of POML-1 with MEC-2 doubled MEC-4(d) channel activity over that in oocytes without POML-1 ([Figure 3A](#F3){ref-type="fig"}), POML-1 did not affect MEC-2 surface expression (Supplemental Figure S6, G and H). In addition, neither POML-1 nor MEC-6 changed total MEC-2 expression in oocytes (Supplemental Figure S6I), stabilized MEC-2 (which moves on the surface of oocytes; [@B14]), or caused it to colocalize with MEC-4 (Supplemental Video S1).

DISCUSSION
==========

MEC-6 is essential for TRN touch sensitivity ([@B10]; [@B13]). Previously the interaction of MEC-4 and MEC-6 ([@B13]) led us to conclude that MEC-6 was a component of the transduction channel. The findings that MEC-4 and MEC-6 do not colocalize on the plasma membrane of *Xenopus* oocytes ([@B14]) and that MEC-6 and the related protein POML-1 fail to localize with MEC-4 and MEC-2 in TRN neurites (this work) argue against MEC-6 and POML-1 being components of the transduction complex. The primary localization of these proteins in the ER, their colocalization with MEC-4 in the ER, and their effect on the expression and localization of MEC-4 suggest that MEC-6 and POML-1 act instead as ER-resident chaperones. Thus MEC-6 and POML-1 represent a new class of chaperones. The effects on functional expression of MEC-6 and POML-1 (and, in the case of MEC-6, on transport) may underlie the increases in MEC-4(d) channel currents that we saw in oocytes. MEC-6 and POML-1, however, are likely to affect relatively few proteins, since general ER stress was not induced in *mec-6* or *poml-1* mutants.

Although both MEC-6 and POML-1 are required for MEC-4 expression and localization, they do not act identically. Specifically, MEC-6, but not POML-1, accelerated the appearance of MEC-4 on the oocyte surface, and SEC-24 proteins partially suppressed the inhibition of *mec-4(d)*--induced TRN cell death caused by *poml-1* but not *mec-6* mutations. These results and the finding that overexpression of *mec-6* or *poml-1* did not rescue mutations in the other gene argue that MEC-6 and POML-1 may have distinct but overlapping roles in MEC-4 channel maturation. In contrast to *mec-6*, *poml-1* mutants still have nearly normal touch sensitivity and MEC-2 puncta, indicating that these animals have a reduced but still sufficient amount of functional MEC-4 in the TRN neurites. This MEC-4 can be detected on the surface of the cultured TRNs but does not form visible puncta in vivo, although they presumably are sufficient enough to allow for the formation of MEC-2 puncta, which depend on MEC-4 ([@B69]). This result agrees with stoichiometry data suggesting that visible MEC-4 puncta are not necessary for the channel function ([@B14]).

In contrast to CRT-1, which has more general functions in cells---for example, facilitating glycoprotein folding and regulating Ca^2+^ homeostasis in the ER ([@B41])---the action of MEC-6 and POML-1 is more restricted. Unlike calreticulin, which can bind up to 25 Ca^2+^ ions ([@B4]; [@B41]), MEC-6 and POML-1 lack a similar Ca^2+^-binding domain or even the two Ca^2+^-binding residues in mammalian PONs ([@B30]) and thus are unlikely to play a direct role in regulating subcellular Ca^2+^ content. Consistent with the absence of Ca^2+^-binding domains in MEC-6 and POML-1, induction of ER Ca^2+^ release by thapsigargin had no effect on the suppression of MEC-4(d) by *mec-6* and *poml-1* (such treatment does affect the suppression by *crt-1*; [@B66]). Moreover, genetic screens for mutations that reverse *poml-1* suppression of MEC-4(d) identified genes that encode MEC-10 and MEC-19, which normally inhibit MEC-4(d) channel activity and surface expression ([@B15]). Therefore the effect of *poml-1*, and perhaps *mec-6*, on MEC-4(d) is largely due to effects on MEC-4 expression and production rather than modulation of cellular Ca^2+^.

Both MEC-6 and POML-1 are needed for the maturation of DEG/ENaC proteins. MEC-6, which is expressed in many neurons and muscles, is needed for the action of gain-of-function (d) mutations affecting several DEG-ENaC proteins (DEG-1 and UNC-8) and ectopically expressed MEC-4(d) but not a gain-of-function, degeneration-causing mutation affecting the nicotinic acetylcholine receptor protein DEG-3 ([@B11]; [@B24]; [@B57]; [@B29]).

The action of MEC-6 and POML-1, however, may not be restricted to only DEG/ENaC proteins, proteins that form amiloride-sensitive channels. That both MEC-6 ([@B13]) and POML-1 (this work) can produce an amiloride-resistant current in oocytes hints that they may act on other proteins. In addition, we found that MEC-6, but not POML-1, increased MEC-2 surface expression by ∼60% in oocytes. POML-1 might affect MEC-2 activity, since POML-1 increased MEC-4(d) channel activity in oocytes with MEC-2 or with MEC-2 and MEC-6 together but not with MEC-6 on its own. Because POML-1 did not change MEC-2 expression in oocytes or in the TRNs, we do not know whether this enhancement was direct---for example, by altering MEC-2 conformation---or indirect through changes in MEC-4.

MEC-6 and POML-1 and the human PONs are ∼27% identical (over the C-terminal 260 residues), and all have an N-terminal hydrophobic region ([@B59]). Of interest, two of the three mammalian PONs---PON2 and PON3---are found in the ER and can reduce the cell death induced by the unfolded protein response ([@B32]; [@B54]). The characterization of MEC-6 and POML-1 in *C. elegans* suggests a novel function of this protein family: ER chaperones that facilitate the maturation and transport of DEG/ENaC and, perhaps in vertebrates, other proteins.

MATERIALS AND METHODS
=====================

*C. elegans* procedures
-----------------------

Unless otherwise indicated, strains were maintained and studied at 20°C on the OP50 strain of *Escherichia coli* according to [@B7]). All of the translational fusions were based on pPD95.75 ([www.addgene.org/static/cms/files/Vec95.pdf](http://www.addgene.org/static/cms/files/Vec95.pdf)). Transgenic animals were prepared by microinjection, and integrated transgenes were generated by ultraviolet irradiation ([@B12]). Details about strains, plasmids, and cDNAs are given in the Supplemental Materials. Ethyl methanesulfonate mutagenesis was performed according to [@B7]) to obtain additional alleles of *poml-1* (see the Supplemental Materials).

We studied gentle touch sensitivity in blind tests as described ([@B10]) and quantified the response by counting the number of responses to 10 touches delivered alternately near the head and tail in 30 animals. We performed in vivo electrophysiology as previously described ([@B47]) and also used blue light and channelrhodopsis-2 expressed in the TRNs to stimulate these cells as previously described ([@B16]). We performed single-molecule fluorescence in situ hybridization to count *mec-4* mRNA as previously described ([@B62]).

Bortezomib (Selleckchem, Houston, TX) was dissolved in dimethyl sulfoxide (DMSO) to make 130 mM stock and added to nematode growth medium (NGM) to make plates containing 50 μM bortezomib. L3 to L4 larvae were transformed onto NGM plates with bortezomib and grown for 8 h. Animals get sick if treated for longer times. In the control group, animals of the same age were transferred to NGM plates containing the same volume of DMSO without bortezomib.

*C. elegans* microscopy and immunofluorescence
----------------------------------------------

Confocal images were acquired using a 63×/numerical aperture 1.40 oil immersion objective on a Zeiss LSM700 confocal microscope (Zeiss, Jena, Germany). Colocalization of MEC-6 and POML-1 with each other and with ER and Golgi markers in the cell body was quantified by the colocalization function in ZEN 2010 software and is represented by Pearson's *R* value. Live animals were anesthetized using 100 mM 2-3-butanedione monoxime in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4.

Fluorescence was observed using a Zeiss Axio Observer Z1 inverted microscope equipped with a Photometrics CoolSnap HQ^2^ camera (Photometrics, Tucson, AZ) and a Zeiss Axioskop II equipped with a SPOT 2 slider camera (SPOT Imaging Solutions, Sterling Heights, MI).

Immunostaining of larvae and adults was performed according to [@B43]), except for MEC-4 immunostaining, which used a mouse anti--MEC-4 antibody (ab22184; Abcam, Cambridge, MA) and was performed according to [@B5]). The following antibodies were used for immunostaining of *C. elegans*: anti--MEC-18 ([@B68]), anti--MEC-2 N-terminus ([@B68]), anti--MEC-4 (mouse, ab22184; Abcam), anti-FLAG (mouse, F1804; Sigma, St. Louis, MO), and anti-GFP (rabbit polyclonal A11122 and mouse monoclonal 3E6; Life Technologies, Carlsbad, CA) diluted 1:200, Rhodamine Red-X--conjugated goat anti-rabbit immunoglobulin G (IgG), Alexa Fluor 488--conjugated goat anti-rabbit IgG, and Alexa Fluor 647--conjugated goat anti-rabbit/mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), and Alexa Fluor 488/555--conjugated goat anti-mouse (Life Technologies) diluted 1:700.

MEC-2 and POML-1 immunofluorescence puncta were analyzed over \~50-μm length of TRN neurites with regular puncta using ImageJ (rsbweb.nih.gov/ij/) and the Puncta Analysis Toolkit beta developed by Mei Zhen (Samuel Lunenfeld Research Institute, Toronto, Canada). The width of puncta was the length at half-maximum of each peak, and the average distance between puncta was calculated as 1/(number of puncta per micrometer). Colocalization of POML-1, MEC-4, MEC-2, and MEC-6 puncta in the TRN neurite was analyzed by ImageJ plug-in Coloc 2 (<http://fiji.sc/Coloc2>) as described in [@B14]).

We measured fluorescence intensity in the cell body by selecting the cell body area (20--30 μm^2^) and measuring the mean intensity subtracted from the background of the same-size area by ImageJ. The intensity of the MEC-4::TagRFP puncta intensity was measured in the best- focused image of six images taken at different *z*-planes using the Puncta Analysis Toolkit beta. Puncta were examined over a region approximately equivalent to 10 cell body lengths starting near the cell body.

Isolated, embryonic TRNs that had been cultured for 15--24 h ([@B70]) were fixed in 4% paraformaldehyde, blocked in phosphate-buffered saline (PBS) with 1% bovine serum albumin (in some experiments, 0.2% Triton-X-100 was added to permeabilize the plasma membrane), incubated with primary antibodies (as indicated) at 4°C for 2 h, washed three times in PBS, incubated with secondary antibodies (Rhodamine Red-X--conjugated goat anti-rabbit IgG and Alexa Fluor 647--conjugated goat anti-mouse IgG diluted 1:2000) at room temperature for 30 min, and washed three times in PBS. Immunofluorescence of MEC-18, a cytoplasmic TRN protein, was used as an internal control for nonpermeabilized immunostaining ([@B17]). Most cell bodies and some neurites became leaky during immunostaining and displayed clear immunofluorescence signal of MEC-18. Only the fluorescence in intact neurites was measured. We quantified the mean immunofluorescence intensity of MEC-4 in the cell body and the neurite by ImageJ.

After immunostaining for MEC-4, cultured TRNs were incubated with ER tracker Blue-White DPX (E12353; Life Technologies) diluted 1:1000 in PBS at room temperature for 30 min and washed three times in PBS before imaging. An anti-EEA1 antibody (ab2900; Abcam) diluted 1:400 was used to label endosome in cultured TRNs. Correlation coefficients of MEC-4 with markers for ER, endosome, and Golgi were analyzed using ImageJ plug-in Coloc 2 as described earlier.

FRET
----

FRET was performed on L4 to young adult animals glued with Dermabond (Ethicon, Somerville, NJ) onto 2% agarose pads according to [@B67]), using a Zeiss LSM700 confocal microscope. Mean fluorescence intensity minus background was determined in the cell body (and in the puncta for wild type) for three channels: CFP (CFP~excitation\ 405\ nm~ -- CFP~emission\ 420--475\ nm~), YFP (YFP~excitation\ 488\ nm~ -- YFP~emission~ ≥ ~520\ nm~), and FRET (CFP~excitation\ 405\ nm~ -- YFP~emission~ ≥ ~520\ nm~). The cross-talk of CFP into the FRET channel (*Df* = FRET/CFP = 84%) was determined in animals expressing *mec-4p::cfp::mec-4*. Similarly, the cross-talk coefficient of YFP to the FRET channel is determined by expressing *mec-4p::mec-4::yfp* only and calculated as *Af* = FRET/YFP = 1.4%. Net FRET was calculated as FRET − 0.84 × CFP − 0.014 × YFP ([@B67]). Normalized FRET was calculated as Net FRET/(CFP × YFP)^1/2^ ([@B65]).

Electrophysiology, biochemistry, and single-molecule imaging in *Xenopus* ooctyes
---------------------------------------------------------------------------------

A 1050--base pair *poml-1* cDNA coding sequence was generated by RACE PCR using the FirstChoice RLM-RACE kit (Ambion, Grand Island, NY) with mRNA from wild-type animals and cloned in pGEM-HE ([@B37]). cDNA of POML-1 was cloned into pGEMHE-EGFP-X ([@B64]) to generate proteins tagged with EGFP at their N-termini.

cRNA expression and electrophysiology in *Xenopus laevis* oocytes (Xenopus I, Dexter, MI; Nasco, Fort Atkinson, WI; Ecocyte, Austin, TX) followed the procedures and used the plasmids previously described ([@B25]). In the experiments described in [Figure 3](#F3){ref-type="fig"}, 10 ng of cRNA of MEC-4, MEC-2, and MEC-10, 1 ng of MEC-6 cRNA, and/or 5 ng of cRNA of POML-1 were injected into oocytes unless noted otherwise. Oocytes were maintained as previously described ([@B2]). Membrane current was measured 4--6 d after cRNA injection using a two-electrode voltage clamp as previously described ([@B25]). In the experiments described in [Figure 7, A and B](#F7){ref-type="fig"}, oocytes were injected with 3.75 ng of MEC-4::EGFP cRNA, 1 ng of MEC-6 cRNA, 3.75 or 7.5 ng of MEC-2 cRNA, and 3.75 or 5 ng of cRNA of POML-1 (no difference was seen for the different MEC-2 and POML-1 injections, and data were pooled). For the remainder of the experiments in [Figure 7](#F7){ref-type="fig"} and Supplemental Figure S6, oocytes were injected with 3.75 ng of Myc::MEC-4(d) cRNA, 1 ng of MEC-6::HA cRNA, 10 ng of MEC-2 cRNA, and 7.5 ng of cRNA of EGFP::POML-1 unless otherwise noted. Coexpression of Myc::MEC-4(d) and tagged MEC-6 and POML-1 produced amiloride-sensitive currents that were similar to those of the coexpressed untagged proteins at different time points (for MEC-4(d) and MEC-6 vs. Myc::MEC-4(d) and MEC-6::HA at 2 d, −0.8 ± 0.1 vs. −0.7 ± 0.1, and at 5--6 d, −1.7 ± 0.3 vs. −1.7 ± 0.3; for MEC-4(d) and POML-1 vs. Myc::MEC-4(d) and EGFP::POML-1 at 2 d, −0.1 ± 0 vs. −0.2 ± 0.1, and at 5--6 d, −0.7 ± 0.2 vs. −0.8 ± 0.1; five oocytes).

Immunoprecipitation was performed 5--6 d after cRNA injection as previously described ([@B25]). Protein complex was precipitated by using the following antibodies conjugated to Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Dallas, TX): antibodies against GFP (rabbit polyclonal sc-8334; Santa Cruz Biotechnology), Myc (rabbit polyclonal sc-789; Santa Cruz Biotechnology), and HA tags (rabbit polyclonal, sc-805; Santa Cruz Biotechnology). Protein samples were subjected to SDS--PAGE and Western blot. Four to eight oocyte equivalents were loaded per lane for immunoprecipitation, and one oocyte equivalent was loaded per lane for total lysate. The specificity of the immunoprecipitation was confirmed in two ways. First, 1 ng of cRNA encoding Myc::EGFP (for Myc::MEC-4(d) immunoprecipitation of EGFP::POML-1), EGFP (for EGFP::POML-1 immunoprecipitation of Myc::MEC-4(d)), and EGFP::HA (for MEC-6::HA immunoprecipitation of EGFP::POML-1) were used as negative controls; none of the proteins was immunoprecipitated. Second, we probed the immunocomplexes for a *Xenopus* oocyte membrane protein, β-integrin, by using a monoclonal antibody (8C8; Developmental Studies Hybridoma Bank, Iowa City, IA) and did not detect the β-integrin.

Protein was detected by Western blot using antibodies against GFP (mouse monoclonal, sc-9996; Santa Cruz Biotechnology), Myc (mouse monoclonal 9E10; Sigma-Aldrich), the HA tags (mouse monoclonal, sc-7392; Santa Cruz Biotechnology), MEC-2 N-terminus (rabbit polyclonal; [@B68]), or actin (rabbit polyclonal, A2066; Sigma-Aldrich) and horseradish peroxidase (HRP)--conjugated secondary antibodies (Jackson ImmunoResearch Laboratories). Horseradish peroxidase was detected using the ECL Western Blotting reagent (Amersham, Little Chalfont, United Kingdom).

Biotinylation assays to detect the surface expression of MEC-4 generally followed the methods described previously ([@B25]). Surface protein was labeled and isolated using the membrane-impermeable EZ-Link Sulfo-NHS-SS-Biotin and NeutrAvidin agarose provided in the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific, Waltham, MA). Samples collected from 30 oocytes from each group were loaded per lane in SDS--PAGE and detected by Western blotting using a primary monoclonal Myc antibody (clone 9E10; Sigma-Aldrich) and HRP-conjugated secondary antibody (Jackson ImmunoResearch Laboratories). The total lysate of one oocyte equivalent was loaded as input. β-Actin was detected in total lysate as an input control by Western blotting using a rabbit polyclonal antibody against actin (A2066; Sigma-Aldrich). Cytoplasmic EGFP was detected in the supernatants but not in the avidin precipitates. Band density was measured from the autoradiography films using ImageJ (National Institutes of Health, Bethesda, MD).

TIRF imaging of oocytes was performed as described in [@B14].

Statistics
----------

Data are presented as mean ± SEM unless noted otherwise. Statistical significance was determined using GraphPad Prism5 software (GraphPad, La Jolla, CA). We used the Student's *t* test (with Welch's correction when data being compared did not have equal variances) for most experiments. For the quantification of MEC-4::EGFP spots on the surface of *Xenopus* oocytes, we used the Mann--Whitney test. For the quantification of Western blot, we used the one-sample *t* test. All *p* values from the Student's *t*, Mann--Whitney, and one-sample *t* test were adjusted with a Bonferroni correction. When three or more groups were compared, we used one-way analysis of variance (ANOVA) with Tukey post hoc or two-way ANOVA with Bonferroni posttests. In the figures, \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001 are corrected *p* values; ns indicates not significant. All values were determined with the Student's *t* test unless noted otherwise.
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:   touch receptor neuron.
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